Safety Evaluation of Recombinant Human Interleukin-4 I. Preclinical Studies

By Leach M.W.   Snyder E.A.   Sinha D.P.   Rosenblum I.Y.  

Clinical Immunology, Vol. 83, Iss. 1, 1997-04 ,pp. : 8-11

Academic Press

Access to resources Recommend Favorite

Safety Considerations of Recombinant Protein Therapy: Introductory Comments

By Hayes T.J.   Ryffel B.  

Clinical Immunology, Vol. 83, Iss. 1, 1997-04 ,pp. : 1-4

Academic Press

Access to resources Recommend Favorite

Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo

By Zocher M.  

International Immunology, Vol. 15, Iss. 7, 2003-07 ,pp. : 789-796

Oxford University Press

Access to resources Recommend Favorite

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

By Dietrich Barbara   Schiviz Alexandra   Hoellriegl Werner   Horling Frank   Benamara Karima   Rottensteiner Hanspeter   Turecek Peter   Schwarz Hans   Scheiflinger Friedrich   Muchitsch Eva-Maria  

International Journal of Hematology, Vol. 98, Iss. 5, 2013-11 ,pp. : 525-532

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical Immunogenicity Testing for Recombinant Therapeutic Proteins

By Smith Holly   Wierda Daniel  

Journal of Immunotoxicology, Vol. 2, Iss. 4, 2005-10 ,pp. : 203-210

Informa Healthcare

Access to resources Recommend Favorite